What’s Next for U.S. Drug Pricing and Domestic Production
APCO hosted a discussion around the recent Trump Administration executive orders on drug pricing and the announcement of using the Defense Production Act to spur increased U.S.-based pharmaceutical ingredients manufacturing as the nation gears up to come back stronger. Panelists were APCO IAC member and policy expert Dr. Kavita Patel; PhRMA General Counsel and former HHS acting general counsel, Jim Stansel; former FDA Chief Counsel and Sidley partner Becky Wood. I had the privilege of serving as moderator.
The discussion covered a range of timely topics including the policy and political ramifications of the executive orders, how drug pricing actions will resonate considering the pandemic and which of these policies might move forward in 2021. We fully discussed the pharmaceutical industry’s strong reaction in opposing the most favored nation pricing proposal, its support of the effort to reform the system of providing rebates to “middlemen” and the challenges of drug importation. The discussion about the Kodak decision focused on the overall supply chain the challenges and opportunities.
Watch the full event here:
